Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas

Abstract

Formation of meningiomas and their progression to malignancy may be a multi-step process, implying accumulation of genetic mutations at specific loci. To determine the relationship between early NF2 gene inactivation and the molecular mechanisms that may contribute to meningioma tumor progression, we have performed deletion mapping analysis at chromosomes 1, 14 and 22 in a series of 81 sporadic meningiomas (54 grade I (typical), 25 grade II (atypical) and two grade III (anaplastic)), which were also studied for NF2 gene mutations. Single-strand conformational polymorphism analysis was used to identify 11 mutations in five of the eight exons of the NF2 gene studied. All 11 tumors displayed loss of heterozygosity (LOH) for chromosome 22 markers; this anomaly was also detected in 33 additional tumors. Twenty-nine and 23 cases were characterized by LOH at 1p and 14q, respectively, mostly corresponding to aggressive tumors that also generally displayed LOH 22. All three alterations were detected in association in seven grade II and two grade III meningiomas, corroborating the hypothesis that the formation of aggressive meningiomas follows a multi-step tumor progression model.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Al Saadi A, Latimer F, Madercic M and Robbins T. . 1987 Cancer Genet. Cytogenet. 26: 127–141.

  • Bandera CA, Hiroyuki T, Behbakht K, Liu PC, LiVolsi VA, Benjamin I, Morgan MA, King SA, Rubin SC and Boyd J. . 1997 Cancer Res. 57: 513–515.

  • Battersby RDE, Ironside JW and Maltby EL. . 1986 J. Neurol. Neurosurg. Psychiatry 49: 362–368.

  • Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Pestaña A and Rey JA. . 1994 Genes Chrom. Cancer 9: 296–298.

  • Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Pestana A and Rey JA. . 1995 Int. J. Cancer 64: 207–210.

  • Bender B, Wiestler OD and von Deimling AA. . 1994 Biotechniques 16: 204–206.

  • Bièche I, Champème M-H and Lidereau RA. . 1994 Cancer Res. 54: 4274–4276.

  • Butti G, Assietti R, Casalone R and Paoletti P. . 1989 Surg. Neurol. 31: 255–260.

  • Casalone R, Simi P, Granata P, Minelli E, Giudici A, Butti G and Solero CL. . 1990 Cancer Genet. Cytogenet. 45: 237–244.

  • Casartelli C, Rogatto SR and Barbieri Neto J. . 1989 Cancer Genet. Cytogenet. 40: 33–45.

  • Chang WY-H, Cairns P, Schoenberg MP, Polascik TJ and Sidransky D. . 1995 Cancer Res. 55: 3246–3249.

  • De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bigozzi U, Montali E and Papi L. . 1996 Hum. Genet. 97: 632–637.

  • Domenicucci M, Santoro A, D'Osvaldo DH, Delfini R, Cantore GP and Guidetti BJ. . 1989 Neurosurg. 70: 41–44.

  • Fearon ER and Vogelstein B. . 1990 Cell 61: 759–767.

  • Feinberg D and Vogelstein B. . 1984 Anal. Biochem. 137: 266–267.

  • Fujino T, Risinger JI, Collins NK, Liu F-S, Nishii H, Takashashi H, Wetsphal EM, Barrett JC, Sasaki H, Kohler MF, Berchuck A and Boyd J. . 1994 Cancer Res. 54: 4294–4298.

  • Harada T, Irving RM, Xuereb JH, Barton DE, Hardy DG, Moffat DA and Maher ER. . 1996 J. Neurosurg. 84: 847–851.

  • Jost CA, Marin MC and Kaelin WG. . 1997 Nature 389: 191–194.

  • Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J-C, Valent A, Minty A, Chalon P, Lelias J-M, Dumont X, Ferrara P, McKeon F and Caput D. . 1997 Cell 90: 809–819.

  • Kleihues P, Burger PC and Scheitauer BW. . 1993 Brain Pathol. 3: 255–268.

  • Kovacs G. . 1993 Histopathol. (Oxf.) 22: 1–8.

  • Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD and von Deimling A. . 1995 J. Neuropathol. Exp. Neurol. 54: 91–95.

  • Lekanne-Deprez RH, Blanchi AB, Groen NA, Seizinger BR, Hagemeijer A, van Drunen E, Bootsma D, Koper JW, Avezaat CJJ, Kley N and Zwarthoff EC. . 1994 Am. J. Hum. Genet. 54: 1022–1029.

  • Lekanne-Deprez RH, Riegman PH, van Drunen E, Warringa UL, Groen NA, Stefanko SZ, Koper JW, Avezaat CJJ, Mulder PGH, Zwarthoff EC and Hagemeijer A. . 1995 J. Neuropathol. Exp. Neurol. 54: 224–235.

  • Lekanne-Deprez RH, Riegman PH, Groen NA, Warringa UL, van Biezen NA, Molijn AC, Bootsma D, de Jong PJ, Menon AG, Kley NA, Seizinger BR and Zwarthoff EC. . 1995 Oncogene 10: 1521–1528.

  • Lindblom A, Ruttledge M, Collins VP, Nordenskjöld M and Dumanski JP. . 1994 Int. J. Cancer 56: 354–357.

  • Lopez-Gines C, Cerda-Nicolas M, Barcia-Salorio JL and Llombart-Bosch A. . 1995 Cancer Genet. Cytogenet. 85: 113–117.

  • Maltby EL, Ironside JW and Battersby RDE. . 1988 Cancer Genet. Cytogenet. 31: 199–210.

  • Martuza RL and Eldridge R. . 1988 New Engl. J. Med. 318: 684–687.

  • Memon MY. . 1980 Neurosurgery 7: 262–264.

  • Menon AG, Rutter JL, von Sattel JP, Synder H, Murdoch C, Blumenfeld A, Martuza RL, von Deimling A, Gusella JF and Houseal TH. . 1997 Oncogene 14: 611–616.

  • Merel P, Hoang-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, Moisan JP, Resche F, Nishisho I, Estivill X, Delatre JY, Poisson M, Theillet C, Hulsebos T, Delattre O and Thomas G. . 1995 Genes Chrom. Cancer 13: 211–216.

  • Mertens F, Johansson B, Höglund M and Mitelman F. . 1997 Cancer Res. 57: 2765–2780.

  • Papi L, De Vitis LR, Vitelli F, Ammannati F, Mennonna P, Montali E and Bigozzi U. . 1995 Hum. Genet. 95: 347–351.

  • Perry A, Jenkins RB, Dahl RJ, Moertel CA and Scheithauer BW. . 1996 Cancer 77: 2567–2573.

  • Peyrard M, Fransson I, Xie Y-G, Huan F-Y, Ruttledge MH, Swahn S, Collins JE, Dunham I, Collins VP and Dumanski JP. . 1994 Hum. Mol. Genet. 3: 1393–1399.

  • Poulsgard L, Ronne M and Schmidek HH. . 1993 In: Molecular Genetics of Nervous System Tumors. Levine AJ and Schmidek HH (eds).. Wiley-Liss: New York. 249–254.

    Google Scholar 

  • Rasio D, Murakumo Y, Robbins D, Roth T, Silver A, Negrini M, Schmidt C, Burczak J, Fishel R and Croce CM. . 1997 Cancer Res. 57: 2378–2383.

  • Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W and Collins VP. . 1994 Am. J. Pathol. 145: 1175–1190.

  • Rempel SA, Schwechheimer K, Davis RL, Cavenee WK and Rosemblum ML. . 1993 Cancer Res. 53: 2386–2392.

  • Rey JA, Bello MJ, de Campos JM, Kusak ME and Moreno S. . 1988 Cancer Genet. Cytogenet. 33: 275–290.

  • Rey JA, Bello MJ, Jimenez-Lara AM, Vaquero J, Kusak ME, de Campos JM, Sarasa JL and Pestaña A. . 1992 Int. J. Cancer 51: 703–706.

  • Rigby PW, Dieckmann M, Rhodes C and Berg P. . 1977 J. Mol. Biol. 113: 237–251.

  • Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldrige R, Aurias A, Delattre O and Thomas G. . 1993 Nature 363: 515–521.

  • Ruttledge MH, Sarrazin J, Rangaratman S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjöld, Collins VP, Dumanski JP and Rouleau GA. . 1994 Nature Genet. 6: 180–184.

  • Schneider BF, Shashi V, von Kap-Herr C and Golden WL. . 1995 Cancer Genet. Cytogenet. 85: 101–104.

  • Schwab M, Praml C and Amler LC. . 1996 Genes Chrom. Cancer 16: 211–229.

  • Simon M, von Deimling A, Larson JL, Wellenreuther R, Kaskel P, Waha A, Warnick RE, Tew JM and Menon AG. . 1995 Cancer Res. 55: 4696–4701.

  • Takayama H, Suzuki T, Mugishima H, Fujisawa T, Ookuni M, Schwab M, Gehring M, Nakamura Y, Sugimura T, Terada M and Yokota J. . 1992 Oncogene 7: 1185–1189.

  • Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ and Gusella JF. . 1993 Cell 72: 791–800.

  • Vagner-Capodano AM, Grisoli F, Gambarelli D, Sedan R, Pellet W and De Victor B. . 1993 Neurosurgery 32: 892–900.

  • Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, Ramesh V, Gusella JF, Wiestler OD and von Deimling A. . 1995 Am. J. Pathol. 146: 827–832.

  • Young J, Leggett B, Ward M, Thomas L, Buttenshaw R, Searle J and Chenevix-Trench G. . 1993 Oncogene 8: 671–675.

  • Zang KD. . 1982 Cancer Genet. Cytogenet. 6: 249–274.

Download references

Acknowledgements

Supported by grant SAF 95/0898, from CICYT. Ministerio de Education y Cultura. We are grateful to Paloma Nebreda for excellent technical assistance. PEL was supported by fellowship from Instituto de Cooperacion Iberoamericana (Programa MUTIS). This work was presented at the AACR special conference on Cancer of the Central Nervous System, San Diego, California, June 1997.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leone, P., Bello, M., Campos, J. et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18, 2231–2239 (1999). https://doi.org/10.1038/sj.onc.1202531

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202531

Keywords

This article is cited by

Search

Quick links